Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyl-5-FU prodrugs

被引:24
|
作者
Beall, HD
Sloan, KB
机构
[1] Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA
[2] Univ Montana, Dept Pharmaceut Sci, Missoula, MT 59812 USA
关键词
3-alkylcarbonyl-5-fluorouracil; S-AQ; S-IPM; K-IPM : AQ; transformed Potts-Guy equation; diffusion cell experiments;
D O I
10.1016/S0378-5173(01)00609-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The solubilities in isopropyl myristate (S-IPM) and pH 4.0 buffer (S-AQ) and the partition coefficients between IPM and pH 4.0 buffer (K-IPM:AQ) have been measured for a series of 3-alkylcarbonyl-5-fluorouracil prodrugs (3-AC-5-FU). The 3-AC-5-FU prodrugs were all 100 times more soluble in IPM and the first two members of the series were also more soluble in pH 4.0 buffer than 5-FU. The abilities of the 3-AC-5-FU prodrugs to deliver total 5-FU species through hairless mouse skin from IPM suspensions (J(i)) were also measured. The 3-propionyl derivative 3, which exhibited the highest S-AQ in the series, gave the highest J(i) value. The S-IPM, S-AQ and molecular weights (mw) of the 3-AC-5-FU series correctly predicted the rank order and very closely (0.10 log units) predicted the absolute values for log J(i) using the transformed Potts-Guy equation. Although the series of 3-AC-5-FU prodrugs was generally quite effective at increasing J(i) (2-20 times), the best 3-AC-5-FU prodrug was not as effective as the best 1-alkylcarbonyl-5-FU prodrug (1-AC-5-FU) at increasing J(i) and the ability of the 3-AC-5-FU prodrugs to increase the concentration of total 5-FU species in the skin was 2-5 times less than the 1-AC-5-FU prodrugs. Thus, the 1-AC-5-FU prodrugs remain as the best prodrugs with which to enhance the topical delivery of 5-FU. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:127 / 137
页数:11
相关论文
共 50 条
  • [21] ISOLATED LIVER PERFUSION WITH 5-FLUOROURACIL (5-FU) IN MAN
    AIGNER, K
    WALTHER, H
    TONN, JC
    KRAHL, M
    WENZL, A
    MERKER, G
    SCHWEMMLE, K
    [J]. CHIRURG, 1982, 53 (09): : 571 - 573
  • [22] EXCRETION OF 5-FLUOROURACIL (5-FU) INTO PANCREATIC-JUICE
    TAKADA, T
    YASUDA, H
    UCHIYAMA, K
    HASEGAWA, H
    [J]. GASTROENTEROLOGY, 1993, 104 (04) : A454 - A454
  • [23] TOLERANCE FOR 5-FLUOROURACIL (5-FU) IN RODENTS RECEIVING HYPERALIMENTATION
    SOUCHON, EA
    COPELAND, EM
    WATSON, P
    DUDRICK, SJ
    [J]. FEDERATION PROCEEDINGS, 1974, 33 (03) : 692 - 692
  • [24] METABOLISM OF 5-FLUOROURACIL (5-FU) IN HUMAN GASTROINTESTINAL CANCER
    BERNE, M
    ALMERSJO, O
    GUSTAVSSON, B
    [J]. ACTA CHIRURGICA SCANDINAVICA, 1983, : 31 - 31
  • [25] 5-FLUOROURACIL(5-FU) IN PRIMARY TRABECULECTOMY - A RANDOMIZED TRIAL
    LOFTFIELD, K
    BALL, SF
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1991, 32 (04) : 745 - 745
  • [26] ALLERGIC CONTACT-DERMATITIS TO 5-FLUOROURACIL (5-FU)
    GOETTE, DK
    ODOM, RB
    [J]. CLINICAL RESEARCH, 1976, 24 (02): : A201 - A201
  • [27] Modulation of plasma pharmacokinetics of 5-fluorouracil (5-FU) by eniluracil
    Abaogye, EO
    Saleem, A
    Osman, S
    Yap, J
    Harte, RJA
    Purnell, C
    O'Callaghan, M
    Lucas, VS
    Jones, T
    Price, PM
    [J]. BRITISH JOURNAL OF CANCER, 1999, 80 : 95 - 95
  • [28] TREATMENT OF EXPERIMENTAL ACUTE PANCREATITIS WITH 5-FLUOROURACIL (5-FU)
    JOHNSON, RM
    BARONE, RM
    NEWSON, BL
    DASGUPTA, TK
    NYHUS, LM
    [J]. AMERICAN JOURNAL OF SURGERY, 1973, 125 (02): : 211 - 222
  • [29] Preoperative chemoradiotherapy with 5-fluorouracil (5-FU) or 5-FU/oxaliplatin (5FU/OX) for rectal cancer is a feasible treatment strategy in the elderly
    Dolinsky, C. M.
    Mahmoud, N. N.
    Mick, R.
    Sun, W.
    Whittington, R.
    Solin, L. J.
    Haller, D. G.
    O'Dwyer, P.
    Fry, R. D.
    Metz, J. M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S308 - S308
  • [30] 5-fluorouracil (5-FU) plasma exposure and outcome in patients receiving a TPF (taxotere, cisplatin, 5-FU) chemotherapy
    Legand, C.
    Blasco, H.
    Benz, I.
    Chapet, C.
    Le Guellec, C.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 25 - 25